Novavax, Inc. (NVAX)
Stock Price:
$157.17 USD
1.30 (0.83%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $172.12 +14.95 (9.51%) Aug 4, 6:17 PM
Key Info
| Market Cap |
9.36B |
| Revenue (ttm) |
18.06M |
| Net Income (ttm) |
-115.34M |
| Shares Out |
58.69M |
| EPS (ttm) |
-3.83 |
| PE Ratio |
n/a |
| Forward PE |
34.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$157.17 |
| Previous Close |
$155.87 |
| Change ($) |
1.30 |
| Change (%) |
0.83% |
| Day's Open |
156.34 |
| Day's Range |
150.28 - 157.30 |
| Day's Volume |
10,604,575 |
| 52-Week Range |
3.54 - 159.97 |
More Stats
| Market Cap |
9.36B |
| Enterprise Value |
9.44B |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
58.69M |
| Float |
54.38M |
| EPS (basic) |
-4.09 |
| EPS (diluted) |
-3.83 |
| FCF / Share |
-2.48 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.50M |
| Short Ratio |
0.98 |
| Short % of Float |
13.90% |
| Beta |
1.49 |
| PE Ratio |
n/a |
| Forward PE |
34.97 |
| P/FCF Ratio |
n/a |
| PS Ratio |
518.63 |
| PB Ratio |
n/a |
| Revenue |
18.06M |
| Operating Income |
-103.26M |
| Net Income |
-115.34M |
| Free Cash Flow |
-110.30M |
| Net Cash |
-76.30M |
| Net Cash / Share |
-1.28 |
| Gross Margin |
-527.11% |
| Operating Margin |
-571.83% |
| Profit Margin |
-638.80% |
| FCF Margin |
-610.84% |
| ROA |
-25.55% |
| ROE |
n/a |
| ROIC |
-29.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
3 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$134.80*
(-14.23% downside)
Low
105
Current: $157.17
High
184
Target: 134.80
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 18.66 | 34.29 | 31.18 | 15.35 | 36.25 | 30.66 | 20.92 | 22.08 | 14.69 | 0.34 |
| Revenue Growth | -45.57% | 9.98% | 103.06% | -57.65% | 18.24% | 46.59% | -5.26% | 50.3% | 4182.22% | - |
| Gross Profit | 18.66 | 34.29 | 31.18 | 15.35 | 36.25 | 30.66 | 20.92 | 7.38 | 7.69 | 0.34 |
| Operating Income | -121 | -174 | -172 | -269 | -157 | -83.69 | -52.43 | -29.67 | -21.58 | -38.49 |
| Net Income | -133 | -185 | -184 | -280 | -157 | -82.95 | -51.98 | -28.51 | -19.36 | -35.71 |
| Shares Outstanding | 24.10 | 18.49 | 14.63 | 13.54 | 13.11 | 11.29 | 8.48 | 6.59 | 5.68 | 5.24 |
| Earnings Per Share | -5.51 | -9.99 | -12.56 | -20.60 | -12.00 | -7.40 | -6.20 | -4.40 | -3.40 | -6.80 |
| Operating Cash Flow | -137 | -185 | -144 | -259 | -126 | -67.01 | -45.36 | -18.23 | -23.63 | -32.85 |
| Capital Expenditures | -1.86 | -1.37 | -4.19 | -18.20 | -18.27 | -7.23 | -5.67 | -4.02 | -0.61 | -1.56 |
| Free Cash Flow | -138 | -186 | -149 | -277 | -144 | -74.24 | -51.03 | -22.25 | -24.24 | -34.41 |
| Cash & Equivalents | 82.18 | 104 | 186 | 270 | 268 | 168 | 134 | 45.85 | 18.31 | 31.68 |
| Total Debt | 321 | 319 | 318 | 316 | 0.40 | 1.00 | 1.88 | 1.21 | 0.32 | 0.40 |
| Net Cash / Debt | -238 | -215 | -131 | -45.96 | 268 | 167 | 133 | 44.65 | 17.99 | 31.28 |
| Assets | 173 | 208 | 302 | 394 | 386 | 276 | 235 | 102 | 66.58 | 74.84 |
| Liabilities | 359 | 376 | 404 | 400 | 93.37 | 46.38 | 31.89 | 22.11 | 12.73 | 15.79 |
| Book Value | -186 | -168 | -102 | -5.55 | 293 | 230 | 203 | 80.24 | 53.85 | 59.05 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Novavax, Inc. |
| Country |
United States |
| Employees |
165 |
| CEO |
Stanley C. Erck |
Stock Information
| Ticker Symbol |
NVAX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NVAX |
| IPO Date |
December 5, 1995 |
Description
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.